238 related articles for article (PubMed ID: 23788833)
21. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
[TBL] [Abstract][Full Text] [Related]
22. Preparation and characterization of biodegradable urea-loaded microparticles as an approach for transdermal delivery.
Haddadi A; Farboud ES; Erfan M; Aboofazeli R
J Microencapsul; 2006 Sep; 23(6):698-712. PubMed ID: 17118885
[TBL] [Abstract][Full Text] [Related]
23. Modulated release of IdUrd from poly (D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers.
Geze A; Venier-Julienne MC; Saulnier P; Varlet P; Daumas-Duport C; Devauchelle P; Benoit JP
J Control Release; 1999 Apr; 58(3):311-22. PubMed ID: 10099156
[TBL] [Abstract][Full Text] [Related]
24. Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition.
Lück M; Pistel KF; Li YX; Blunk T; Müller RH; Kissel T
J Control Release; 1998 Nov; 55(2-3):107-20. PubMed ID: 9795026
[TBL] [Abstract][Full Text] [Related]
25. Ketoprofen-poly(D,L-lactic-co-glycolic acid) microspheres: influence of manufacturing parameters and type of polymer on the release characteristics.
Gabor F; Ertl B; Wirth M; Mallinger R
J Microencapsul; 1999; 16(1):1-12. PubMed ID: 9972498
[TBL] [Abstract][Full Text] [Related]
26. Structured Biodegradable Polymeric Microparticles for Drug Delivery Produced Using Flow Focusing Glass Microfluidic Devices.
Ekanem EE; Nabavi SA; Vladisavljević GT; Gu S
ACS Appl Mater Interfaces; 2015 Oct; 7(41):23132-43. PubMed ID: 26423218
[TBL] [Abstract][Full Text] [Related]
27. Preparation, characterization, and in vitro evaluation of 1- and 4-month controlled release orntide PLA and PLGA microspheres.
Kostanski JW; Thanoo BC; DeLuca PP
Pharm Dev Technol; 2000; 5(4):585-96. PubMed ID: 11109259
[TBL] [Abstract][Full Text] [Related]
28. In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method.
Niwa T; Takeuchi H; Hino T; Kunou N; Kawashima Y
J Pharm Sci; 1994 May; 83(5):727-32. PubMed ID: 8071830
[TBL] [Abstract][Full Text] [Related]
29. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist.
Du L; Cheng J; Chi Q; Qie J; Liu Y; Mei X
Chem Pharm Bull (Tokyo); 2006 Sep; 54(9):1259-65. PubMed ID: 16946531
[TBL] [Abstract][Full Text] [Related]
30. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA.
Capan Y; Woo BH; Gebrekidan S; Ahmed S; DeLuca PP
J Control Release; 1999 Aug; 60(2-3):279-86. PubMed ID: 10425333
[TBL] [Abstract][Full Text] [Related]
31. β-methasone-containing biodegradable poly(lactide-co-glycolide) acid microspheres for intraarticular injection: effect of formulation parameters on characteristics and in vitro release.
Song X; Song SK; Zhao P; Wei LM; Jiao HS
Pharm Dev Technol; 2013; 18(5):1220-9. PubMed ID: 22295954
[TBL] [Abstract][Full Text] [Related]
32. Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone.
Kim HK; Chung HJ; Park TG
J Control Release; 2006 May; 112(2):167-74. PubMed ID: 16542746
[TBL] [Abstract][Full Text] [Related]
33. Influence of PLGA molecular weight distribution on leuprolide release from microspheres.
Ochi M; Wan B; Bao Q; Burgess DJ
Int J Pharm; 2021 Apr; 599():120450. PubMed ID: 33675924
[TBL] [Abstract][Full Text] [Related]
34. Controlled protein release from monodisperse biodegradable double-wall microspheres of controllable shell thickness.
Xia Y; Ribeiro PF; Pack DW
J Control Release; 2013 Dec; 172(3):707-14. PubMed ID: 23954731
[TBL] [Abstract][Full Text] [Related]
35. Porous bone morphogenetic protein-2 microspheres: polymer binding and in vitro release.
Schrier JA; DeLuca PP
AAPS PharmSciTech; 2001 Oct; 2(3):E17. PubMed ID: 14727876
[TBL] [Abstract][Full Text] [Related]
36. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
Mehta AK; Yadav KS; Sawant KK
Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
[TBL] [Abstract][Full Text] [Related]
37. Biodegradable Nanoparticles-Loaded PLGA Microcapsule for the Enhanced Encapsulation Efficiency and Controlled Release of Hydrophilic Drug.
Ryu S; Park S; Lee HY; Lee H; Cho CW; Baek JS
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33801871
[TBL] [Abstract][Full Text] [Related]
38. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres.
Sinha VR; Trehan A
Drug Deliv; 2005; 12(3):133-9. PubMed ID: 16025842
[TBL] [Abstract][Full Text] [Related]
39. Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process.
Ruan G; Feng SS; Li QT
J Control Release; 2002 Dec; 84(3):151-60. PubMed ID: 12468218
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems.
Schrier JA; DeLuca PP
Pharm Dev Technol; 1999; 4(4):611-21. PubMed ID: 10578516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
